AA
KLRS

ALPS Advisors’s Kalaris Therapeutics KLRS Stock Holding History

ALPS Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,621
Closed -$238K – 1035
2023
Q1 		$238K Sell
2,621
-125
-5% -$15.9K ﹤0.01% 965
2022
Q4 		$324K Buy
2,746
+536
+24% +$90.9K ﹤0.01% 810
2022
Q3 		$401K Buy
2,210
+523
+31% +$81.5K ﹤0.01% 658
2022
Q2 		$151K Sell
1,687
-1,233
-42% -$129K ﹤0.01% 1009
2022
Q1 		$453K Sell
2,920
-358
-11% -$71.4K ﹤0.01% 446
2021
Q4 		$975K Sell
3,278
-192
-6% -$89.1K 0.01% 363
2021
Q3 		$2M Sell
3,470
-258
-7% -$119K 0.02% 319
2021
Q2 		$1.69M Sell
3,728
-1,393
-27% -$719K 0.02% 346
2021
Q1 		$2.76M Buy
5,121
+4
+0.1% +$3.36K 0.03% 225
2020
Q4 		$4.52M Buy
+5,117
New +$3.94M 0.05% 181

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

ALPS Advisors's KLRS Position: Q2 2023 in Review

ALPS Advisors sold out of Kalaris Therapeutics (KLRS) in Q2 2023, closing a stake of 2,621 shares — an estimated $238K sold.

ALPS Advisors first reported a position in KLRS in Q4 2020 and held it in 10 quarters. The position peaked at $4.52M in Q4 2020. 94 funds tracked by Wall St. Rank hold KLRS as of Q2 2023.

  • ALPS Advisors reported no remaining Kalaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 2,621 Kalaris Therapeutics shares in Q2 2023, an estimated $238K.
  • ALPS Advisors first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 10 quarters.
  • ALPS Advisors's Kalaris Therapeutics position peaked at $4.52M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.